Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

samarium Sm-153 lexidronam pentasodium

The pentasodium salt of samarium Sm 153 lexidronam, a therapeutic agent consisting of a medium energy beta- and gamma-emitting radioisotope, samarium Sm 153, and a teraphosphonate chelator, ethylenediaminetetramethylene phosphonic acid (EDTMP). The chelator moiety of samarium Sm 153 lexidronam associates with hydroxyapatite crystals concentrated in areas of bone turnover, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to osteoblastic bone metastases.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	samarium Sm 153 lexidronam pentasodium samarium Sm-153 EDTMP pentasodium samarium-153 EDTMP pentasodium Sm 153 lexidronam pentasodium
US brand name:	Quadramet

samarium Sm-153 lexidronam pentasodium

Search NCI's Drug Dictionary